Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biopharmaceutical firm Isotechnika has been issued a Norwegian patent for its lead immunosuppressive drug, ISA247. Obtaining the patent in Norway completes the protection over the novel structural features of ISA247 in Europe.
Subscribe to our email newsletter
A total of 83 patents worldwide have been issued relating to ISA247’s structure, composition, formulation and methods of synthesis. ISA247 is currently being investigated in a Phase IIb North American trial for the prevention of kidney graft rejection subsequent to transplantation and a Phase III European/Canadian psoriasis trial.
Robert Foster, Isotechnika’s chairman and CEO, said: “In accordance with our overall strategic plan, we continue to secure patent protection worldwide in anticipation of acquiring market approval for ISA247. This indicates that ISA247 will have exclusivity for at least another 15 years. Additional claims for ISA247 will be pursued to ensure that intellectual property is secured in all of the major markets worldwide.”